Chemoprevention of colorectal cancer in inflammatory bowel disease

Digestive and Liver Disease

Volumn 41, Issue 5, 2009, Pages 338-339

  Butterworth, J R ^a  

^a PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SALAZOSULFAPYRIDINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER RISK; COLITIS; COLON CARCINOGENESIS; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; HIGH RISK PATIENT; HUMAN; LOSS OF FUNCTION MUTATION; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROTEIN INDUCTION; RISK REDUCTION; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

EID: 63049133610     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.01.011     Document Type: Note

References (10)

1. Eaden J.A., Abrams K.R., and Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (2001) 526-535
2. Aust D.E., Terdiman J.P., Willenbucher R.F., Chang C.G., Molinaro-Clark A., Baretton G.B., et al. The APC/βcatenin pathway in ulcerative colitis-related colorectal carcinomas. Cancer 94 (2002) 1421-1427
3. Kern S.E., Redston M., Seymour A.B., Caldas C., Powell S.M., Kornacki S., et al. Molecular genetic profiles of colitis associated neoplasm. Gastroenterology 107 (1994) 420-428
4. Yashiro M., Carethers J.M., Laghi L., Saito K., Slezak P., Jaramillo E., et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasm. Cancer Res 61 (2001) 2676-2683
5. Meltzer S.J., Mane S.M., Wood P.K., Resau J.H., Newkirk C., Terzakis J.A., et al. Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products. Cancer Res 50 (1990) 3627-3630
6. Karlen P., Kornfeld D., Brostrom O., Lofberg R., Persson P.G., and Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 42 (1998) 711-714
7. Dubuquoy L., Bourdon C., Peuchmaur M., Leibowitz M.D., Nutten S., Colombel J.F., et al. Peroxisome proliferator activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease. Gastroenterol Clin Biol 24 (2000) 719-724
8. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104 (1999) 383-389
9. Lewis J.D., Lichtenstein G.R., Stein R.B., Deren J.J., Judge T.A., Fogt F., et al. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 96 (2001) 3323-3328
10. Neve B.P., Fruchart J.C., and Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 60 (2000) 1245-1250